The lung cancer therapeutics market size was valued at USD 32.83 billion in 2024 and is expected to reach USD 61.08 billion by 2032, growing at a CAGR of 8.08% over 2025-2032.
The global lung cancer therapeutics market is gaining attraction as the prevalence of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) continues to increase, the growing awareness of the early diagnosis of lung cancer, and various technological advancements. Targeted therapies, immunotherapies (e.g., PD-1/PD-L1 inhibitors), and companion diagnostics continue to redefine treatment paradigms.
In May 2025, the promising Phase III data of Tagrisso for early-stage NSCLC (released by AstraZeneca) contributed to further shifting the move toward adjuvant targeted therapy.
The ageing of the world’s population, along with more widespread exposure to risk factors such as air pollution and smoking, is contributing to a growing burden of disease and therefore demand for care. Investments in R&D by pharmaceutical companies are substantial, and global spending on oncology R&D is expected to exceed USD 90 billion in 2024, with a substantial proportion for lung cancer.
Regulatory agencies such as the FDA and EMA have expedited approval of breakthrough therapies (i.e., Tepmetko, Lumakras, Enhertu). Moreover, biotech collaborations and licensing agreements are also stoking those innovation pipelines. Improved success rates of clinical trials are enabling increased patient access to novel therapies and benefiting the global lung cancer therapeutics market.
In April 2025, Roche Ventana launched a 3rd-generation blood-based companion diagnostic for EGFR mutations, furthering trends of personalized medicine in the lung cancer therapeutics market analysis.
Drivers:
Rising Innovation, Demand for Precision Medicine, and Regulatory Support Propel Market Expansion
The lung cancer therapeutics market is expected to be primarily driven by a rising prevalence of lung cancer, demand for personalized medicine, and growing R&D focus on the development of innovative technologies. Lung cancer is one of the most common and lethal cancers globally, and the need for better therapy has led to progress. The arrival of biomarker-based therapies and NGS tools is making personalized treatment strategies a reality.
For instance, Pfizer and EMD Serono’s Lorbrena and Novartis’ Tabrecta have already demonstrated impressive effectiveness in ALK- and MET-altered NSCLCs, respectively.
Global investment in Oncology R&D exceeded USD 91 billion in 2024, featuring more than 500 trials targeting lung cancer. In addition, fast-track mechanisms, including breakthrough therapy designation by the FDA and the EMA’s PRIME scheme, are making the path to market even quicker for potential game-changing therapies, such as antibody-drug conjugates, bispecific T-cell engagers. Further, a surge in public and private funding, the emergence of new clinical trial infrastructure, and rising collaboration between pharma and biotech players are expected to drive robust lung cancer therapeutics market growth. Furthermore, increasing patient awareness, acceptance of immunotherapy in first-line therapy, and use of AI in clinical development are some factors assisting in defining the emerging global lung cancer therapeutics market trends.
Restraints:
High Cost, Drug Resistance, and Limited Access in Developing Nations Hamper Market Growth
The lung cancer therapeutics market has certain restraining factors, such as high cost of treatments, development of resistance towards the drugs, and low healthcare facilities in low-income economies. At or above USD 150,000 annually per patient on average, these immunotherapies, such as nivolumab and pembrolizumab, are prohibitively expensive, and their costs are not covered by insurance in many markets. In addition, the emergence of acquired resistance to EGFR and ALK inhibitors continues to be a significant clinical hurdle. It has been reported that as many as 60% of patients treated with first-generation EGFR tyrosine kinase inhibitors (TKIs) are resistant after 12 months.
Supply chain limitations and insufficient cold-chain infrastructure in the developing world limit access to sophisticated therapeutics. Additionally, regulatory obstacles in certain countries, unstandardized testing of actionable mutations, and a lack of uniform healthcare reimbursement policies are barriers to its full penetration. The multiplicity and duration of clinical trials also contribute to the expense of development and lengthen the time to launch the drug. All these obstacles affect the lung cancer therapeutics market size and hinder equitable patient access, particularly in areas with low investment in diagnostic and treatment infrastructure.
By Therapy
Targeted therapy was the largest therapy segment in 2024, contributing to more than 56.6% of the global lung cancer therapeutics market share. Its dominance is driven by its high efficacy, relative lack of side effects compared to traditional therapies, and growing adoption of precision medicine that selectively targets genes like EGFR, ALK, and ROS1. These treatments have led to an increase in progression-free survival in patients with NSCLC. In contrast, immunotherapy is estimated to add more to the growth. As indications continue to expand for ICIs and combination strategies become increasingly standard of care in the front-line setting, immunotherapy is revolutionizing treatment paradigms for both NSCLC and SCLC.
By Lung Cancer Type
Based on prevalence, non-small cell lung cancer (NSCLC) led the market in 2024, making up almost 85% of total lung cancer incidences, as well as its increased responsiveness to targeted and immunotherapies. The small cell lung cancer (SCLC) market is anticipated to be the fastest-growing segment; however, recent therapeutic advancements, such as immunotherapy-based regimens (e.g., atezolizumab with chemotherapy) and emerging biomarker-based strategies, are improving historically poor outcomes.
By Distribution Channel
In 2024, hospital pharmacies were the leading distribution channel owing to the direct availability of specialty drugs and treatment provision infrastructure. Hospitals are important sites of delivery, where therapies such as infusions and complex treatment schedules can be modified. Nevertheless, online source is expected to be the fastest growing segment owing to the growing trend toward digitalization of the healthcare industry, preference of patients for home delivery, rising availability of oral targeted therapy and maintenance drugs via digital channels.
By Type of Molecule
In 2024, small molecules were leading the market due to their ease of consumption (primarily oral) and lower manufacturing costs, and they can cross cell membranes for intracellular targets. These are the EGFR, ALK, and BRAF inhibitors, which are standard in advanced NSCLC therapy. The biologics segment is witnessing the fastest CAGR as a result of the increasing usage of monoclonal antibodies and immune checkpoint inhibitors. The trend is also supported by the introduction of new biologic formats, for instance, bispecific antibodies and antibody-drug conjugates.
By Drug Class
By drug class, EGFR inhibitors accounted for the most revenues in 2024 since EGFR mutations were highly prevalent in patients with NSCLC, particularly in the Asian region. Osimertinib and such drugs have established themselves as the standard first-line treatments because they work better and are better tolerated. Multikinase inhibitors are estimated to be the most rapidly growing class as they can target several pathways at the same time, and therefore can be used against resistant or heterogeneous tumours. Their use is increasing in the second-line and refractory settings, and the demand is increasing.
North America led the lung cancer therapeutics market due to the high prevalence and diagnosis rate of lung cancer (as compared to other regions), increasing demand for target therapy & chemotherapy, personalized medicines, and strong presence of leading players in this region.
The U.S. lung cancer therapeutics market size was valued at USD 9.51 billion in 2024 and is expected to reach USD 15.86 billion by 2032, growing at a CAGR of 6.65% over 2025-2032. By country, the U.S. is dominant its strong pharmaceutical presence, high per capita healthcare expenditure, and central drug approvals by the FDA. In the U.S. in 2023, there were more than 238,000 new cases of lung cancer, and the growing number of these cases is increasing demand for both immunotherapy and drugs targeting specific genetic mutations. Moreover, the increasing use of next-generation sequencing and companion diagnostics further boosts the proliferation of personalized medicine. There is an increasing number of clinical trials and government support for oncology innovation in Canada in turn leads to steady market growth. National cancer control programs in Mexico have started to improve access; however, the infrastructure is still a limiting factor in comparison to its northern neighbors.
Europe holds a considerable share in the lung cancer therapeutics market on account of high awareness, as well as government-funded healthcare systems, and increasing adoption of biologics and target therapies. The up-front test region is dominated by the UK, which has high uptake of NHS-approved immunotherapies, lung cancer screening programs, and a healthy academix–industry partnership in oncology trials. The European Medicines Agency (EMA) has authorised several treatments for lung cancer in the past few years, such as nivolumab and osimertinib, improving patients' access. Germany and France are also leading donors by virtue of generous reimbursement policies and early implementation of combined therapy protocols. Poland and Turkey are proving to be particularly important second-tier markets, with the former experiencing rapid growth due to incremental clinical trial participation and the latter developing oncology infrastructure.
The fastest-growing market in the lung cancer therapeutics market is Asia Pacific, on the back of growing lung cancer incidents, increasing healthcare spending, diagnostics penetration, and pharmaceutical R&D centers. China dominates the region, with the largest global burden of lung cancer; over 800,000 new cases were reported in 2024, and significant government support for domestic innovation through its Healthy China 2030 initiative. Local companies like BeiGene and Innovent are attracting attention around the world for their innovative immunotherapies. India is growing as well, as it sees an increase in patients with cancer, government mandates around the use of biosimilars, and higher uptake of digital health platforms. Japan, a country with high healthcare standards and an ageing population, has high uptake of approved targeted therapies and predictable reimbursement pathways. South Korea and Singapore are new biotech innovation hubs contributing to the regional development and growth of drug development and clinical trials.
Leading lung cancer therapeutics companies operating in the market comprise AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co., Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Johnson & Johnson, Amgen Inc., and Novartis AG.
In May 2025, NHS England rolled out a nationwide liquid biopsy for lung cancer patients, enabling tumor DNA profiling via a simple blood test. This “liquid biopsy–first” approach delivers results up to 16 days faster, boosting early access to targeted therapies and saving the NHS approximately USD 13.9 million annually.
In May 2025, U.S. FDA grants accelerated approval to AbbVie’s Emrelis (telisotuzumab vedotin), an antibody-drug conjugate targeting c–Met–overexpressing NSCLC. Based on a mid-stage trial with a 35% overall response rate, this approval paves the way for late-stage efficacy testing.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 32.83 billion |
| Market Size by 2032 | USD 61.08 billion |
| CAGR | CAGR of 8.08% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Therapy (Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, and Others) • By Lung Cancer Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Lung Carcinoid Tumor) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) • By Type of Molecule (Small Molecules, Biologics) • By Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co., Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Johnson & Johnson, Amgen Inc., and Novartis AG. |
Ans: The Lung Cancer Therapeutics market is anticipated to grow at a CAGR of 8.08% from 2025 to 2032.
Ans: The market is expected to reach USD 61.08 billion by 2032, increasing from USD 32.83 billion in 2024.
Ans: The lung cancer therapeutics market is expected to be primarily driven by a rising prevalence of lung cancer, demand for personalized medicine, and growing R&D focus on the development of innovative technologies.
Ans: The lung cancer therapeutics market has certain restraining factors, such as high cost of treatments, development of resistance towards the drugs, and low healthcare facilities in low-income economies.
Ans: North America dominated the Lung Cancer Therapeutics market.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Prescription Trends (2024), by Region
5.3 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket), 2024
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Lung Cancer Therapeutics Market Segmentation, By Therapy
7.1 Chapter Overview
7.2 Radiation Therapy
7.2.1 Radiation Therapy Market Trends Analysis (2021-2032)
7.2.2 Radiation Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Targeted Therapy
7.3.1 Targeted Therapy Market Trends Analysis (2021-2032)
7.3.2 Targeted Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Immunotherapy
7.4.1 Immunotherapy Market Trends Analysis (2021-2032)
7.4.2 Immunotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Chemotherapy
7.5.1 Chemotherapy Market Trends Analysis (2021-2032)
7.5.2 Chemotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2021-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Lung Cancer Therapeutics Market Segmentation, By Lung Cancer Type
8.1 Chapter Overview
8.2 Small Cell Lung Cancer
8.2.1 Small Cell Lung Cancer Market Trends Analysis (2021-2032)
8.2.2 Small Cell Lung Cancer Market Size Estimates And Forecasts To 2032 (USD Billion)
8.3 Non-Small Cell Lung Cancer
8.3.1 Non-Small Cell Lung Cancer Market Trends Analysis (2021-2032)
8.3.2 Non-Small Cell Lung Cancer Market Size Estimates And Forecasts To 2032 (USD Billion)
8.4 Lung Carcinoid Tumor
8.4.1 Lung Carcinoid Tumor Market Trends Analysis (2021-2032)
8.4.2 Lung Carcinoid Tumor Market Size Estimates And Forecasts To 2032 (USD Billion)
2032 (USD Billion)
9. Lung Cancer Therapeutics Market Segmentation, By Distribution Channel
Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates And Forecasts To 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies Market Size Estimates And Forecasts To 2032 (USD Billion)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Online Pharmacies Market Size Estimates And Forecasts To 2032 (USD Billion)
10. Lung Cancer Therapeutics Market By Type of Molecule
10.1 Chapter Overview
10.2 Small Molecules
10.2.1 Small Molecules Market Trends Analysis (2021-2032)
10.2.2 Small Molecules Market Size Estimates And Forecasts To 2032 (USD Billion)
10.3 Biologics
10.3.1 BiologicsMarket Trends Analysis (2021-2032)
10.3.2 BiologicsMarket Size Estimates And Forecasts To 2032 (USD Billion)
11. Automotive Ambient Lighting Market, By Drug Class
11.1 Chapter Overview
11.2 Alkylating Agents
11.2.1 Alkylating Agents Market Trends Analysis (2021-2032)
11.2.2 Alkylating Agents Market Size Estimates And Forecasts To 2032 (USD Billion)
11.3 Antimetabolites
11.3.1 Antimetabolites Market Trends Analysis (2021-2032)
11.3.2 Antimetabolites Market Size Estimates And Forecasts To 2032 (USD Billion)
11.4 EGFR Inhibitors
11.4.1 EGFR Inhibitors Market Trends Analysis (2021-2032)
11.4.2 EGFR Inhibitors Market Size Estimates And Forecasts To 2032 (USD Billion)
11.4 Mitotic Inhibitors
11.4.1 Mitotic Inhibitors Market Trends Analysis (2021-2032)
11.4.2 Mitotic Inhibitors Market Size Estimates And Forecasts To 2032 (USD Billion)
11.5 Multikinase Inhibitors
11.5.1 Multikinase Inhibitors Market Trends Analysis (2021-2032)
11.5.2 Multikinase Inhibitors Market Size Estimates And Forecasts To 2032 (USD Billion)
11.6 Others
11.6.1 Others Market Trends Analysis (2021-2032)
11.6.2 Others Market Size Estimates And Forecasts To 2032 (USD Billion)
12. Regional Analysis
12.1 Chapter Overview
12.2 North America
12.2.1 Trends Analysis
12.2.2 North America Lung Cancer Therapeutics Market Estimates And Forecasts, By Country (2021-2032) (USD Billion)
12.2.3 North America Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.2.4 North America Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.2.5 North America Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.2.6 North America Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.2.7 North America Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.2.8 USA
12.2.8.1 USA Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.2.8.2 USA Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.2.8.3 USA Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.2.8.4 USA Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.2.8.5 USA Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.2.9 Canada
12.2.9.1 Canada Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.2.9.2 Canada Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.2.9.3 Canada Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.2.9.4 Canada Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.2.9.5 Canada Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.2.10 Mexico
12.2.10.1 Mexico Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.2.10.2 Mexico Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.2.10.3 Mexico Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.2.10.4 Mexico Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.2.10.5 Mexico Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3 Europe
12.3.1 Trends Analysis
12.3.2 Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Country (2021-2032) (USD Billion)
12.3.3 Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.4 Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.5 Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.6 Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.7 Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.8 Poland
12.3.8.1 Poland Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.8.2 Poland Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.8.3 Poland Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.8.4 Poland Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.8.5 Poland Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.9 Turkey
12.3.9.1 Turkey Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.9.2 Turkey Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.9.3 Turkey Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.9.4 Turkey Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.9.5 Turkey Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.10 Germany
12.3.10.1 Germany Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.10.2 Germany Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.10.3 Germany Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.10.4 Germany Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.10.5 Germany Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.11 France
12.3.11.1 France Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.11.2 France Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.11.3 France Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.11.4 France Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.11.5 France Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.12 UK
12.3.12.1 UK Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.12.2 UK Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.12.3 UK Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.12.4 UK Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.12.5 UK Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.13 Italy
12.3.13.1 Italy Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.13.2 Italy Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.13.3 Italy Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.13.4 Italy Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.13.5 Italy Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.14 Spain
12.3.14.1 Spain Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.14.2 Spain Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.14.3 Spain Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.14.4 Spain Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.14.5 Spain Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.3.15 Rest Of Europe
12.3.15.1 Rest Of Western Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.3.15.2 Rest Of Western Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.3.15.3 Rest Of Western Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.3.15.4 Rest Of Western Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.3.15.5 Rest Of Western Europe Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4 Asia Pacific
12.4.1 Trends Analysis
12.4.2 Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Country (2021-2032) (USD Billion)
12.4.3 Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.4 Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.5 Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.6 Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.7 Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.8 China
12.4.8.1 China Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.8.2 China Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.8.3 China Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.8.4 China Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.8.5 China Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.9 India
12.4.9.1 India Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.9.2 India Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.9.3 India Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.9.4 India Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.9.5 India Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.10 Japan
12.4.10.1 Japan Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.10.2 Japan Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.10.3 Japan Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.10.4 Japan Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.10.5 Japan Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.11 South Korea
12.4.11.1 South Korea Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.11.2 South Korea Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.11.3 South Korea Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.11.4 South Korea Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.11.5 South Korea Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.12 Singapore
12.4.12.1 Singapore Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.12.2 Singapore Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.12.3 Singapore Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.12.4 Singapore Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.12.5 Singapore Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.13 Australia
12.4.13.1 Australia Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.13.2 Australia Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.13.3 Australia Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.13.4 Australia Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.13.5 Australia Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.4.14 Rest Of Asia Pacific
12.4.14.1 Rest Of Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.4.14.2 Rest Of Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.4.14.3 Rest Of Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.4.14.4 Rest Of Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.4.14.5 Rest Of Asia Pacific Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.5 Middle East And Africa
12.5.1 Trends Analysis
12.5.2 Middle East And Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Country (2021-2032) (USD Billion)
12.5.3 Middle East And Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.5.4 Middle East And Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.5.5 Middle East And Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.5.6 Middle East And Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.5.7 Middle East And Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.5.8 UAE
12.5.8.1 UAE Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.5.8.2 UAE Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.5.8.3 UAE Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.5.8.4 UAE Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.5.8.5 UAE Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.5.9 Saudi Arabia
12.5.9.1 Saudi Arabia Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.5.9.2 Saudi Arabia Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.5.9.3 Saudi Arabia Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.5.9.4 Saudi Arabia Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.5.9.5 Saudi Arabia Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.5.10 Qatar
12.5.10.1 Qatar Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.5.10.2 Qatar Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.5.10.3 Qatar Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.5.10.4 Qatar Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.5.10.5 Qatar Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.5.11 South Africa
12.5.11.1 South Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.5.11.2 South Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.5.11.3 South Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.5.11.4 South Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.5.11.5 South Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.5.12 Rest Of Africa
12.5.12.1 Rest Of Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.5.12.2 Rest Of Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.5.12.3 Rest Of Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.5.12.4 Rest Of Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.5.12.5 Rest Of Africa Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.6 Latin America
12.6.1 Trends Analysis
12.6.2 Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Country (2021-2032) (USD Billion)
12.6.3 Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.6.4 Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.6.5 Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.6.6 Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.6.7 Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.6.8 Brazil
12.6.8.1 Brazil Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.6.8.2 Brazil Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.6.8.3 Brazil Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.6.8.4 Brazil Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.6.8.5 Brazil Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.6.9 Argentina
12.6.9.1 Argentina Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.6.9.2 Argentina Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.6.9.3 Argentina Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.6.9.4 Argentina Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.6.9.5 Argentina Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
12.6.10 Rest Of Latin America
12.6.10.1 Rest Of Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Therapy (2021-2032) (USD Billion)
12.6.10.2 Rest Of Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Lung Cancer Type (2021-2032) (USD Billion)
12.6.10.3 Rest Of Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12.6.10.4 Rest Of Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Type of Molecule (2021-2032) (USD Billion)
12.6.10.5 Rest Of Latin America Lung Cancer Therapeutics Market Estimates And Forecasts, By Drug Class (2021-2032) (USD Billion)
13. Company Profiles
13.1 AstraZeneca
13.1.1 Company Overview
13.1.2 Financial
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.2 Boehringer Ingelheim
13.2.1 Company Overview
13.2.2 Financial
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.3 Bristol-Myers Squibb
13.3.1 Company Overview
13.3.2 Financial
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.4 Eli Lilly and Company
13.4.1 Company Overview
13.4.2 Financial
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.5 Hoffmann-La Roche
13.5.1 Company Overview
13.5.2 Financial
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.6 Merck & Co.
13.6.1 Company Overview
13.6.2 Financial
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.7 Pfizer Inc.
13.7.1 Company Overview
13.7.2 Financial
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.8 Allergan Inc.
13.8.1 Company Overview
13.8.2 Financial
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.9 Teva Pharmaceutical Industries Ltd.
13.9.1 Company Overview
13.9.2 Financial
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.10 AbbVie Inc.
13.10.1 Company Overview
13.10.2 Financial
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
14. Use Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Therapy
Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others
By Lung Cancer Type
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Lung Carcinoid Tumor
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Type of Molecule
Small Molecules
Biologics
By Drug Class
Alkylating Agents
Antimetabolites
EGFR Inhibitors
Mitotic Inhibitors
Multikinase Inhibitors
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players